Skip to content
Clinical Trials – home
Therapeutic area

Immune system disorders – page 33

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Study on Ruxolitinib for Treating Inclusion Body Myositis in Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Assistance Publique Hopitaux De Paris

Study of Avapritinib for Adults with Systemic Mastocytosis Who Previously Participated in an Avapritinib Study

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Avapritinib
  • Sponsor:Blueprint Medicines Corp.

Dermatomyositis+4

Recruiting

Study on Upadacitinib for Patients with Idiopathic Inflammatory Myopathies After Stopping IVIG

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:Medical University Of Vienna

SAPHO syndrome

Recruiting

Study on the Effectiveness and Safety of Etanercept for Patients with SAPHO Syndrome

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Etanercept
  • Sponsor:Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher

Study Comparing Rituximab and KYV-101 for Patients with Active, ACPA-Positive, Treatment-Resistant Rheumatoid Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Kyv-101
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study on Omeprazole and Cow's Milk-Free Diet for Treating Gastroesophageal Reflux Disease in Infants Under 1 Year

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Omeprazole
  • Sponsor:Odense University Hospital

Study of Elenestinib for Patients with Indolent Systemic Mastocytosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elenestinib Phosphate
  • Sponsor:Blueprint Medicines Corp.

Lupus nephritis

Recruiting

Study of Obinutuzumab and Mycophenolate Mofetil Without Oral Corticosteroids for Treatment of Lupus Nephritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Assistance Publique Hopitaux De Paris

Study of High-Dose Vitamin C (Ascorbic Acid) Compared to Placebo in Patients with Sepsis and Acute Respiratory Distress Syndrome (ARDS) in Intensive Care

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Ascorbate
  • Sponsor:Assistance Publique Hopitaux De Paris

Study on the Effects of Methylprednisolone and Prednisone for Treating Acute Flare-Ups in Idiopathic Pulmonary Fibrosis Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:GIE Groupe hospitalier Paris Saint-Joseph/Vinci

Comparing Anakinra versus Immunoglobulin for Treatment-Resistant Kawasaki Disease in Patients Who Failed Initial Immunoglobulin Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Anakinra
  • Sponsor:Assistance Publique Hopitaux De Paris

Multiple sclerosis+2

Recruiting

Study on the Effects of Ozanimod on Inflammation in Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ozanimod
  • Sponsor:Azienda Ospedaliera Universitaria Integrata Verona

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.